Pharmacokinetics and safety of a new generic lurasidone: a phase I bioequivalence study in healthy Chinese subjects
Zhengzhi Liu(The Affiliated Hospital to Changchun University of Chinese Medicine), Haimiao Yang(The Affiliated Hospital to Changchun University of Chinese Medicine), Yingzi Cui(The Affiliated Hospital to Changchun University of Chinese Medicine), Qiaohuan Deng(Changchun University of Chinese Medicine), Xinyao Qu(The Affiliated Hospital to Changchun University of Chinese Medicine), Wanhua Wang(The Affiliated Hospital to Changchun University of Chinese Medicine), Tianying Chang(The Affiliated Hospital to Changchun University of Chinese Medicine), Lixiu Zhang(Qingdao Agricultural University), Lang Liu(Beijing Institute of Technology), Zeyu Wang(Anhui University), Jiahui Chen(The Affiliated Hospital to Changchun University of Chinese Medicine), Yanli Wang(Sun Yat-sen University), Jinling Xue, Nan Xiao(Dalian University of Technology), Wei Yang(The Affiliated Hospital to Changchun University of Chinese Medicine), Yicheng Zhao(Jilin University), Yannan Zhou(The Affiliated Hospital to Changchun University of Chinese Medicine), Guangwen Liu(The Affiliated Hospital to Changchun University of Chinese Medicine)
Cited by 2
Related Papers
Glioma targeted therapy: insight into future of molecular approaches
|Molecular Cancer|2022|727
Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer
|Journal of Experimental & Clinical Cancer Research|2021|535
Interfacial Residual Stress Relaxation in Perovskite Solar Cells with Improved Stability
|Advanced Materials|2019|476
Advances in the Application of Perovskite Materials
|Nano-Micro Letters|2023|408
Immune checkpoint modulators in cancer immunotherapy: recent advances and emerging concepts
|Journal of Hematology & Oncology|2022|273